Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carbapenem-Resistant <i>Acinetobacter baumannii</i> and <i>Klebsiella pneumoniae</i>: A Propensity Score-Matched Cohort Study



Zha, Lei, Zhang, Xue, Cheng, Yusheng, Xu, Qiancheng, Liu, Lingxi, Chen, Simin, Lu, Zhiwei, Guo, Jun and Tefsen, Boris ORCID: 0000-0001-6668-217X
(2023) Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carbapenem-Resistant <i>Acinetobacter baumannii</i> and <i>Klebsiella pneumoniae</i>: A Propensity Score-Matched Cohort Study. ANTIBIOTICS-BASEL, 12 (2). 273-.

[thumbnail of Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carb.pdf] PDF
Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carb.pdf - Open Access published version

Download (1MB) | Preview

Abstract

Although the combination of polymyxin and tigecycline is widely used in treating carbapenem-resistant bacterial infections, the benefit of this combination is still uncertain. To assess whether adding polymyxin B to the high-dose tigecycline regimen would result in better clinical outcomes than the high-dose tigecycline therapy in patients with pneumonia caused by carbapenem-resistant <i>Klebsiella pneumoniae</i> and <i>Acinetobacter baumannii</i>, we conducted a propensity score-matched cohort study in a single center between July 2019 and December 2021. Of the 162 eligible patients, 102 were included in the 1:1 matched cohort. The overall 14-day mortality in the matched cohort was 24.5%. Compared with high-dose tigecycline, the combination therapy was not associated with better clinical outcomes, and showed similar 14-day mortality (OR, 0.72, 95% CI 0.27-1.83, <i>p</i> = 0.486), clinical cure (OR, 1.09, 95% CI 0.48-2.54, <i>p</i> = 0.823), microbiological cure (OR, 0.96, 95% CI 0.39-2.53, <i>p</i> = 0.928) and rate of nephrotoxicity (OR 0.85, 95% CI 0.36-1.99, <i>p</i> = 0.712). Subgroup analyses also did not demonstrate any statistical differences. Based on these results, it is reasonable to recommend against adding polymyxin B to the high-dose tigecycline regimen in treating pneumonia caused by carbapenem-resistant <i>K. pneumoniae</i> and <i>A. baumannii</i>.

Item Type: Article
Uncontrolled Keywords: Acinetobacter baumannii, carbapenem resistance, Klebsiella pneumoniae, nosocomial infection, pneumonia, polymyxin, tigecycline
Divisions: Faculty of Health and Life Sciences
Depositing User: Symplectic Admin
Date Deposited: 06 Jul 2023 13:53
Last Modified: 18 Oct 2023 11:33
DOI: 10.3390/antibiotics12020273
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3171487